A well-recognized molecular mechanism involved in BTZ resistance is the activation of the canonical NF-κB pathway in MM cells (Hideshima et al., 2009), with increased NF-κB activity seen in MM patients who are refractory to BTZ treatment (Markovina et al., 2008). This evidence concerns the gene NFKB1 and Miyoshi myopathy.